ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Clinical and prognostic implications of RAS mutations in metastatic colorectal cancer.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRAS mutations play a critical role in the pathogenesis and progression of colorectal cancer. This study aimed to evaluate the clinical and pathological characteristics associated with RAS mutation status and to investigate its prognostic value in patients with metastatic colorectal cancer.
methodsThis retrospective study included 446 adult patients with metastatic colorectal cancer followed at Dokuz Eylul University Medical Oncology Department between 2010 and 2016, all of whom had available RAS mutation data and complete clinical records.
resultsRAS mutations were identified in 44.8% of patients, predominantly KRAS codon 12 mutations. Early-stage disease and absence of metastasis at diagnosis were more common in the RAS wild-type (WT) group (p < 0.001). Lung metastases occurred more frequently in RAS-mutant cases (p = 0.006). No significant difference in overall survival (OS) was observed between RAS-mutant and WT groups (53.6 vs. 52.5 months; p > 0.05). Anti-VEGF therapy conferred a modest OS benefit in RAS-mutant patients, whereas anti-EGFR therapy showed no effect. Among KRAS-mutant subtypes, codon 61 mutations were associated with the poorest OS.
conclusionRAS mutation status may provide insight into metastatic patterns and disease stage in patients with metastatic colorectal cancer. However, its impact on overall survival remains inconclusive. Further prospective studies are needed to clarify its prognostic value.
Indexed as
Identifiers
41417446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.